Stock Movers Vanda Pharmaceuticals Up, Nike Gains, Biggest Winners of 2025
Dec 31, 2025
Vanda Pharmaceuticals celebrates a significant boost as the FDA approves its motion sickness drug, the first in 40 years. Nike's CEO showcases confidence with a $1 million stock purchase, reflecting strong market sentiment. The S&P 500 is expected to rise over 17% in 2025, primarily fueled by enthusiasm for AI and data storage stocks. However, economic tariffs create challenges for consumer goods and healthcare sectors, leading to notable declines for certain retailers.
AI Snips
Chapters
Transcript
Episode notes
Host Shares Seasickness Experience
- Valerie Teitel mentions personal seasickness when taking the ferry as a segue into the Vanda approval story.
- She frames the drug as potentially helpful for common travel nausea like ferry or car sickness.
First New Motion-Sickness Drug In Decades
- Vanda Pharmaceuticals won FDA approval for Nereus (tradipitant), the first drug for motion-induced vomiting in over 40 years.
- The drug blocks a brain receptor linked to nausea and vomiting and could address sea and car sickness.
Insider Buys Signal Nike Confidence
- Nike shares rose after CEO Elliott Hill bought about $1 million in stock, signaling confidence in a turnaround strategy.
- The move followed Tim Cook doubling his Nike stake, and Nike remains down about 19% year-to-date amid tariff-driven retail headwinds.